We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Something completely different

24 Mar 2011 By Robert Cyran

The drug giant’s years of expansion haven’t fattened shareholders’ wallets. With executives responsible for bloating Pfizer leaving, it’s a good time for a fresh start. Spinning off the animal health, consumer and nutrition units looks a profitable way to slim down.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)